ArticleClinicoEconomics and outcomes research : CEOR2024

Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Sergio Di Matteo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.